In a recently published paper we show that inhibiting cholesterol can alter radiation response of breast cancer cells (MCF7), using a FDA approved compound that inhibits the gene diacylglycerol acyltransferase 2 (DGAT2) involved in the final step of the synthesis of triglycerides in which diacylglycerol is covalently bound to long chain fatty acyl-CoAs [58]. The gene discussed is DGAT2; the disease is breast cancer.